Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

News Daily News

Andexanet Alfa Pulled From US Market

Todd Neale

December 22, 2025

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Daily News

Testosterone Doesn’t Cause CV Events in High-Risk Men With Hypogonadism

Caitlin E. Cox

June 16, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Opinion CV Team Dispatch

June 2022 News Roundup

L.A. McKeown

June 01, 2022

News Daily News

Could an App Replace Statin Prescribing by Doctors?

Michael O'Riordan

September 08, 2021

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Daily News

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

Michael O'Riordan

August 21, 2019

News Daily News

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Yael L. Maxwell

August 14, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

News Daily News

FDA Adds Boxed Warning About CV Risks to Gout Drug Febuxostat

Shelley Wood

February 22, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

News Daily News

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Michael O'Riordan

April 24, 2018

Advertisement

Andexanet Alfa Pulled From US Market

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Top Endovascular News of 2023

Testosterone Doesn’t Cause CV Events in High-Risk Men With Hypogonadism

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

June 2022 News Roundup

Could an App Replace Statin Prescribing by Doctors?

FDA Approves Icosapent Ethyl for Reducing CVD Events

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

No Need for Niacin? Meta-analysis Argues the End Is Nigh

FDA Adds Boxed Warning About CV Risks to Gout Drug Febuxostat

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

TCTMD’s Top 10 Most Popular Stories for January 2019

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content